Wikipedia

MSX-3

MSX-3 is a selective adenosine A2A receptor antagonist used in scientific research.[1][2] Similarly to MSX-4, it is a water-soluble ester prodrug of MSX-2.[2][3][4]

MSX-3
Clinical data
Drug classAdenosine A2A receptor antagonist
Identifiers
  • 3-[8-[(E)-2-(3-methoxyphenyl)ethenyl]-7-methyl-2,6-dioxo-1-prop-2-ynylpurin-3-yl]propyl dihydrogen phosphate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC21H23N4O7P
Molar mass474.410 g·mol−1
3D model (JSmol)
  • CN1C(=NC2=C1C(=O)N(C(=O)N2CCCOP(=O)(O)O)CC#C)/C=C/C3=CC(=CC=C3)OC
  • InChI=1S/C21H23N4O7P/c1-4-11-25-20(26)18-19(24(21(25)27)12-6-13-32-33(28,29)30)22-17(23(18)2)10-9-15-7-5-8-16(14-15)31-3/h1,5,7-10,14H,6,11-13H2,2-3H3,(H2,28,29,30)/b10-9
  • Key:DUCGTTGSVYZHJS-MDZDMXLPSA-N

Medicinal chemistry

edit

MSX-3, MSX-4, and MSX-2 are xanthines and are derivatives of the non-selective adenosine receptor antagonist caffeine.[5][6] MSX-2 has been extensively studied due to its high affinity and selectivity for the adenosine A2A receptor, but use of MSX-2 itself has been limited by its poor water solubility.[5][2]

Whereas MSX-3 is a phosphate ester prodrug of MSX-2 that is suited best for intravenous administration and not for oral administration, MSX-4 is an amino acid ester (L-valine) prodrug of MSX-2 that can be orally administered.[2][7]

Pharmacology

edit

MSX-2 has 500-fold higher affinity for the adenosine A2A receptor over the adenosine A1 receptor, 580-fold higher affinity for the adenosine A2A receptor over the adenosine A2B receptor, and is inactive at the adenosine A3 receptor.[5][6][8]

MSX-3 itself also showed some affinity for the adenosine receptors, but this may have just been due to degradation by phosphatases in the in vitro system.[6]

Animal studies

edit

MSX-3 shows pro-motivational effects in animals.[1][9] Specifically, although it showed no effect on its own, the drug reverses the effort-related deficits induced by the dopamine depleting agent tetrabenazine (TBZ), the dopamine D2 receptor antagonists haloperidol and eticlopride, and the proinflammatory cytokines interleukin-6 and interleukin-1β.[1][9][10][11][12][13]

Conversely, it only mildly attenuates the motivational deficits induced by the dopamine D1 receptor antagonist ecopipam (SCH-39166).[10][14]

History

edit

MSX-3 was first described in the scientific literature by 1998.[3][4] A similar agent, MSX-4, was subsequently described by 2008.[2][7]

References

edit
  1. ^ a b c Salamone JD, Correa M, Ferrigno S, Yang JH, Rotolo RA, Presby RE (October 2018). "The Psychopharmacology of Effort-Related Decision Making: Dopamine, Adenosine, and Insights into the Neurochemistry of Motivation". Pharmacological Reviews. 70 (4): 747–762. doi:10.1124/pr.117.015107. PMC 6169368. PMID 30209181.747-762&rft.date=2018-10&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169368#id-name=PMC&rft_id=info:pmid/30209181&rft_id=info:doi/10.1124/pr.117.015107&rft.aulast=Salamone&rft.aufirst=JD&rft.au=Correa, M&rft.au=Ferrigno, S&rft.au=Yang, JH&rft.au=Rotolo, RA&rft.au=Presby, RE&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169368&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  2. ^ a b c d e Müller CE (November 2009). "Prodrug approaches for enhancing the bioavailability of drugs with low solubility". Chemistry & Biodiversity. 6 (11): 2071–2083. doi:10.1002/cbdv.200900114. PMID 19937841.2071-2083&rft.date=2009-11&rft_id=info:doi/10.1002/cbdv.200900114&rft_id=info:pmid/19937841&rft.aulast=Müller&rft.aufirst=CE&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  3. ^ a b Müller CE, Sauer R, Maurinsh Y, Huertas R, Fülle F, Klotz KN, et al. (1998). "A2A-selective adenosine receptor antagonists: Development of water-soluble prodrugs and a new tritiated radioligand". Drug Development Research. 45 (3–4): 190–197. doi:10.1002/(SICI)1098-2299(199811/12)45:3/4<190::AID-DDR16>3.0.CO;2-A. ISSN 0272-4391.3–4&rft.pages=190-197&rft.date=1998&rft_id=info:doi/10.1002/(SICI)1098-2299(199811/12)45:3/4<190::AID-DDR16>3.0.CO;2-A&rft.issn=0272-4391&rft.aulast=Müller&rft.aufirst=CE&rft.au=Sauer, R&rft.au=Maurinsh, Y&rft.au=Huertas, R&rft.au=Fülle, F&rft.au=Klotz, KN&rft.au=Nagel, J&rft.au=Hauber, W&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  4. ^ a b Hauber W, Nagel J, Sauer R, Müller CE (June 1998). "Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen". NeuroReport. 9 (8): 1803–1806. doi:10.1097/00001756-199806010-00024. PMID 9665604.1803-1806&rft.date=1998-06&rft_id=info:doi/10.1097/00001756-199806010-00024&rft_id=info:pmid/9665604&rft.aulast=Hauber&rft.aufirst=W&rft.au=Nagel, J&rft.au=Sauer, R&rft.au=Müller, CE&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  5. ^ a b c de Lera Ruiz M, Lim YH, Zheng J (May 2014). "Adenosine A2A receptor as a drug discovery target". Journal of Medicinal Chemistry. 57 (9): 3623–3650. doi:10.1021/jm4011669. PMID 24164628.3623-3650&rft.date=2014-05&rft_id=info:doi/10.1021/jm4011669&rft_id=info:pmid/24164628&rft.aulast=de Lera Ruiz&rft.aufirst=M&rft.au=Lim, YH&rft.au=Zheng, J&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  6. ^ a b c Yuzlenko O, Kieć-Kononowicz K (2006). "Potent adenosine A1 and A2A receptors antagonists: recent developments". Current Medicinal Chemistry. 13 (30): 3609–3625. doi:10.2174/092986706779026093. PMID 17168726.3609-3625&rft.date=2006&rft_id=info:doi/10.2174/092986706779026093&rft_id=info:pmid/17168726&rft.aulast=Yuzlenko&rft.aufirst=O&rft.au=Kieć-Kononowicz, K&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  7. ^ a b Vollmann K, Qurishi R, Hockemeyer J, Müller CE (February 2008). "Synthesis and properties of a new water-soluble prodrug of the adenosine A 2A receptor antagonist MSX-2". Molecules. 13 (2): 348–359. doi:10.3390/molecules13020348. PMC 6244838. PMID 18305423.348-359&rft.date=2008-02&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244838#id-name=PMC&rft_id=info:pmid/18305423&rft_id=info:doi/10.3390/molecules13020348&rft.aulast=Vollmann&rft.aufirst=K&rft.au=Qurishi, R&rft.au=Hockemeyer, J&rft.au=Müller, CE&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244838&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  8. ^ Khayat MT, Hanif A, Geldenhuys WJ, Nayeem MA (2019). "Adenosine Receptors and Drug Discovery in the Cardiovascular System". In Choudhary MI (ed.). Frontiers in Cardiovascular Drug Discovery: Volume 4. Amazon Digital Services LLC - Kdp. pp. 16–64. ISBN 978-1-68108-400-8. Retrieved 23 September 2024.16-64&rft.pub=Amazon Digital Services LLC - Kdp&rft.date=2019&rft.isbn=978-1-68108-400-8&rft.aulast=Khayat&rft.aufirst=MT&rft.au=Hanif, A&rft.au=Geldenhuys, WJ&rft.au=Nayeem, MA&rft_id=https://books.google.com/books?id=R6SXDwAAQBAJ&pg=PA16&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  9. ^ a b López-Cruz L, Salamone JD, Correa M (2018). "Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression". Frontiers in Pharmacology. 9: 526. doi:10.3389/fphar.2018.00526. PMC 5992708. PMID 29910727.
  10. ^ a b Salamone JD, Correa M, Farrar AM, Nunes EJ, Collins LE (5 May 2010). "Role of dopamine–adenosine interactions in the brain circuitry regulating effort-related decision making: insights into pathological aspects of motivation". Future Neurology. 5 (3): 377–392. doi:10.2217/fnl.10.19. hdl:10234/35900. ISSN 1479-6708.377-392&rft.date=2010-05-05&rft_id=info:hdl/10234/35900&rft.issn=1479-6708&rft_id=info:doi/10.2217/fnl.10.19&rft.aulast=Salamone&rft.aufirst=JD&rft.au=Correa, M&rft.au=Farrar, AM&rft.au=Nunes, EJ&rft.au=Collins, LE&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  11. ^ Mott AM, Nunes EJ, Collins LE, Port RG, Sink KS, Hockemeyer J, et al. (May 2009). "The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure". Psychopharmacology. 204 (1): 103–112. doi:10.1007/s00213-008-1441-z. PMC 2875244. PMID 19132351.103-112&rft.date=2009-05&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875244#id-name=PMC&rft_id=info:pmid/19132351&rft_id=info:doi/10.1007/s00213-008-1441-z&rft.aulast=Mott&rft.aufirst=AM&rft.au=Nunes, EJ&rft.au=Collins, LE&rft.au=Port, RG&rft.au=Sink, KS&rft.au=Hockemeyer, J&rft.au=Müller, CE&rft.au=Salamone, JD&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875244&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  12. ^ Nunes EJ, Randall PA, Estrada A, Epling B, Hart EE, Lee CA, et al. (February 2014). "Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task". Psychopharmacology. 231 (4): 727–736. doi:10.1007/s00213-013-3285-4. PMC 4468782. PMID 24136220.727-736&rft.date=2014-02&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468782#id-name=PMC&rft_id=info:pmid/24136220&rft_id=info:doi/10.1007/s00213-013-3285-4&rft.aulast=Nunes&rft.aufirst=EJ&rft.au=Randall, PA&rft.au=Estrada, A&rft.au=Epling, B&rft.au=Hart, EE&rft.au=Lee, CA&rft.au=Baqi, Y&rft.au=Müller, CE&rft.au=Correa, M&rft.au=Salamone, JD&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468782&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  13. ^ Yohn SE, Arif Y, Haley A, Tripodi G, Baqi Y, Müller CE, et al. (October 2016). "Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization". Psychopharmacology. 233 (19–20): 3575–3586. doi:10.1007/s00213-016-4392-9. PMID 27497935.19–20&rft.pages=3575-3586&rft.date=2016-10&rft_id=info:doi/10.1007/s00213-016-4392-9&rft_id=info:pmid/27497935&rft.aulast=Yohn&rft.aufirst=SE&rft.au=Arif, Y&rft.au=Haley, A&rft.au=Tripodi, G&rft.au=Baqi, Y&rft.au=Müller, CE&rft.au=Miguel, NS&rft.au=Correa, M&rft.au=Salamone, JD&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
  14. ^ Worden LT, Shahriari M, Farrar AM, Sink KS, Hockemeyer J, Müller CE, et al. (April 2009). "The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists". Psychopharmacology. 203 (3): 489–499. doi:10.1007/s00213-008-1396-0. PMC 2875246. PMID 19048234.489-499&rft.date=2009-04&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875246#id-name=PMC&rft_id=info:pmid/19048234&rft_id=info:doi/10.1007/s00213-008-1396-0&rft.aulast=Worden&rft.aufirst=LT&rft.au=Shahriari, M&rft.au=Farrar, AM&rft.au=Sink, KS&rft.au=Hockemeyer, J&rft.au=Müller, CE&rft.au=Salamone, JD&rft_id=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875246&rfr_id=info:sid/en.wikipedia.org:MSX-3" class="Z3988">
Retrieved from "https://en.wikipedia.org/w/index.php?title=MSX-3&oldid=1255809278"